Vir Biotechnology reports Phase 3 hepatitis delta trial meets primary and key secondary endpoints
Vir Biotechnology announced that its Phase 3 ECLIPSE 1 trial of elebsiran and tobevibart met the primary endpoint, with 44% of treated patients achieving undetectable HDV RNA and normalized ALT at Week 48, and 79% achieving undetectable virus at the same time point. The 124‑patient study also showed 85% of cirrhotic patients virus‑free. The company plans a global regulatory filing for the U.S. FDA in mid‑2027 and expects data from ECLIPSE 2 and 3 in Q1 2027.



